Verrica Pharmaceuticals, Inc. (VRCA) Received a Third Complete Response Letter from the FDA relating to its New Drug Application for VP-102
Robbins LLP is investigating Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws. Verrica is a dermatology therapeutics company that develops medications for viral skin diseases requiring medical intervention.
Verrica has spent several years working to bring to market VP-102, the Company’s investigational, proprietary, drug-device combination for the treatment of molluscum contagiosum. However, several challenges have prevented this from happening. Verrica received its first Complete Response Letter (CRL) regarding the New Drug Application (NDA) in July 2020 and its second in September 2021. On May 24, 2022, Verrica received yet another CRL from the FDA related to its NDA for VP-102. On this news, the Company’s stock price fell 63.85%, to close at $2.01 per share on May 25, 2022.
Next Steps: If you own shares of Verrica Pharmaceuticals Inc. (VRCA), you have legal options. Contact Robbins LLP for more information.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.